Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
This membrane protein is Human PD-L1 / B7-H1 (19-238). It has been tested in SDS-PGAE, ELISA, alphaLISA. We provide this protein to facilitate your membrane protein antibody discovery and development.
Product Specifications
Host Species
Human
Target Protein
PD-L1 / B7-H1
Protein Length
ECD
Molecular Weight
The protein has a calculated MW of 53.6 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Sequence
AA Phe 19- Arg 238 (Accession # Q9NZQ7-1)
Product Description
Activity
Yes
Application
SDS-PGAE, ELISA, alphaLISA
Expression Systems
HEK293
Tag
Human IgG1 Fc at the C-terminus, followed by a Avi tag
Protein Format
Soluble
Reconstitution
Please see Certificate of Analysis for specific instructions.
Endotoxin
<1.0 EU/μg by the LAL method
Conjugation
Biotin
Purity
>90% as determined by SDS-PAGE
Buffer
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, (pH7.5). Trehalose is added as protectant before lyophilization.
Please contact us for customized formulation or product form if needed.
Target
Target Protein
PD-L1 / B7-H1
Full Name
CD274 molecule
Introduction
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.